Benzinga
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. Lundbeck A/S have received FDA approval for Rexulti (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer's disease. This approval makes Rexulti the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer's disease. It is reported in approximately half of people with Alzheimer's dementia and is associated with earlier nursi
Benzinga